Ex-Ab­b­Vie part­ner Prin­cip­ia posts en­cour­ag­ing PhII re­sults for its BTK-in­hibitor

Months af­ter their breakup with high-pro­file part­ner Ab­b­Vie, Prin­cip­ia an­nounced pos­i­tive pre­lim­i­nary re­sults from the sec­ond half of a Phase II tri­al on their lead drug.

The San Fran­cis­co biotech an­nounced da­ta from part B of its Phase II open-la­bel tri­al test­ing the BTK in­hibitor PRN1008 on pa­tients with pem­phi­gus vul­garis, a rare au­toim­mune dis­ease af­fect­ing the skin and mu­cous mem­branes. Of 15 en­rolled pa­tients, 6 achieved com­plete re­spons­es and 4 re­main on the ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER